Cancer News and Research

Latest Cancer News and Research

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

ZIOPHARM Oncology, Inc. announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The analysis evaluated 62 patients treated as of the end of September, with 58 being analyzed.

14 Oct 2009

EMEA grants ArQule's ARQ 197 orphan drug designation

ArQule, Inc. today announced that the European Medicines Evaluation Agency (EMEA) has designated ARQ 197 as an orphan medical product for the treatment of soft tissue sarcoma.

14 Oct 2009

Riga Eastern Clinical University Hospital commences treatment with the Novalis Tx radiosurgery platform

Doctors in Latvia have begun treatments using the region's first Novalis Tx(TM) radiosurgery platform from Varian Medical Systems and BrainLAB. Two prostate cancer patients have been treated using Varian's RapidArc® radiotherapy technology at the Riga Eastern Clinical University Hospital.

14 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

22nd Healthcare Facilities Symposium & Expo successfully celebrated

The 22nd Healthcare Facilities Symposium & Expo (HFSE) celebrated yet another successful showing at its annual conference, held September 30 - October 2, 2009 at Chicago’s famed Navy Pier. Despite industry-wide concerns about the economy’s impact on tradeshows, HFSE closed the conference unscathed with 2,199 attendees, nearly matching last year’s record high.

14 Oct 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.

14 Oct 2009

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Progenics Pharmaceuticals, Inc. today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth under which Progenics is regaining all worldwide rights to the RELISTOR® franchise from Wyeth Pharmaceuticals, which Progenics had previously licensed to Wyeth Pharmaceuticals.

14 Oct 2009

Women with breast cancer can improve their mental health through Transcendental Meditation technique

Women with breast cancer reduced stress and improved their mental health and emotional well being through the Transcendental Meditation technique, according to a new study published in the current issue of the peer-reviewed Integrative Cancer Therapies (Vol. 8, No. 3: September 2009).

14 Oct 2009

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Research scientists from Massachusetts General Hospital, Boston, have developed a novel bioengineered treatment that has shown promise in targeting pancreatic cancer without causing damage to healthy noncancer cells, a typical problem of chemotherapy.

14 Oct 2009

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

Study: Psychiatrists can distinguish competent defendants from incompetent ones

Court cases across America often feature expert testimony that offers conflicting conclusions. When this happens in cases involving psychiatric expertise, does it mean that one side or the other is necessarily being less than honest?

14 Oct 2009

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) today announced that a presentation on L-DOS47 formulation and analytical method development will be made at the "Formulation Strategies for Protein Therapeutics" conference to be held on October 13 to 15, 2009, in Raleigh, North Carolina. The conference is sponsored by IBC Life Sciences.

14 Oct 2009

O-Cedar's initiative for breast cancer awareness

Fifteen women emerged from 47,000 votes on over 700 essay entries as the 2009 winners of the O-Cedar "Hope Helpers Awards" national essay contest. The essay contest awards each winner $1,000 to help them fulfill a wish or dream that will make life easier for those affected by breast cancer.

14 Oct 2009

CeloNova BioSciences' Embozene Microspheres receives approval

CeloNova BioSciences, Inc. has received approval from its European regulatory body, the British Standards Institution, to expand the list of medical indications for which Embozene(TM) Microspheres may be used and to add a tenth size of the product.

14 Oct 2009

OSUCCC-James and Global Vision Technologies collaborate to deliver a web-based patient registry solution

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) has entered into a contract with Global Vision Technologies (GVT) to create and deliver a new, web-based Photo Dynamic Therapy patient registry solution -- ClinicalPURSUIT -- to help streamline the data collection and outcomes analysis process.

14 Oct 2009

MUC1 protein defends against the stomach ulcer bacterium, according to study

A special protein in the lining of the stomach has been shown to be an important part of the body's defense against the stomach ulcer bacterium Helicobacter pylori in a new study from the Sahlgrenska Academy at the University of Gothenburg. The discovery may explain why the bacterium makes some people more ill than others.

14 Oct 2009

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

Integrated Diagnostics launched officially today with more than $30 million in funding. A pre-eminent team of scientists and investors are behind the company, which was founded by renowned biotechnology innovator Dr. Leroy Hood. Integrated Diagnostics will focus on developing personalized and preventive diagnostics based on breakthroughs using genomic and proteomic technologies to identify organ-specific proteins.

14 Oct 2009

Cancer News and Research

Latest Cancer News and Research

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

EMEA grants ArQule's ARQ 197 orphan drug designation

Riga Eastern Clinical University Hospital commences treatment with the Novalis Tx radiosurgery platform

Abbott announces financial results for the third quarter ended Sept. 30, 2009

22nd Healthcare Facilities Symposium & Expo successfully celebrated

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Women with breast cancer can improve their mental health through Transcendental Meditation technique

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Breakthrough in pancreatic cancer treatment

Study: Psychiatrists can distinguish competent defendants from incompetent ones

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

O-Cedar's initiative for breast cancer awareness

CeloNova BioSciences' Embozene Microspheres receives approval

OSUCCC-James and Global Vision Technologies collaborate to deliver a web-based patient registry solution

MUC1 protein defends against the stomach ulcer bacterium, according to study

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

NY Senators co-sponsors bill to establish comprehensive program for lung cancer

Institute of Medicine elects researcher from The Children's Hospital of Philadelphia as its member

HTDS to release its next 90 to 180 day forward guidance report

Understanding the DNA Damage Response in Innate Immunity eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

The evolution of OCT for retinal imaging and disease intervention

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Prof. Dr. Kristina Kusche-Vihrog

Newsletters you may be interested in